Iranian Journal of Radiology

Published by: Kowsar

Ocular Biodistribution of 89Zr-Bevacizumab in New Zealand Rabbits Determined Using PET/MRI: A Feasibility Study

Xiaoyuan Liu 1 , Jianqiang Ye 2 , Yan Zhang 3 , Quan Liu 4 , Ruizhen Bai 1 , Wenbo Yuan 1 , Dongyan Cai 4 , Xiaoyuan Zheng 1 , Yun Bian 1 , Shijun Zhou 1 , Juan Lv 1 , Yongjuan Ding 1 , Fen Xie 1 , Hongwen Lu 1 and Bingxue Xie 1 , 3 , *
Authors Information
1 Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, China
2 Department of Pathology, Wuxi Huishan District People’s Hospital, Wuxi, China
3 Department of Pharmacy, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, Jiangsu, China
4 Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China
Article information
  • Iranian Journal of Radiology: 16 (2); e68697
  • Published Online: January 23, 2019
  • Article Type: Research Article
  • Received: March 16, 2018
  • Revised: December 12, 2018
  • Accepted: December 18, 2018
  • DOI: 10.5812/iranjradiol.68697

To Cite: Liu X, Ye J, Zhang Y, Liu Q, Bai R, et al. Ocular Biodistribution of 89Zr-Bevacizumab in New Zealand Rabbits Determined Using PET/MRI: A Feasibility Study, Iran J Radiol. Online ahead of Print ; 16(2):e68697. doi: 10.5812/iranjradiol.68697.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Bashir U, Mallia A, Stirling J, Joemon J, MacKewn J, Charles-Edwards G, et al. PET/MRI in oncological imaging: State of the art. Diagnostics (Basel). 2015;5(3):333-57. doi: 10.3390/diagnostics5030333. [PubMed: 26854157]. [PubMed Central: PMC4665605].
  • 2. Garibotto V, Heinzer S, Vulliemoz S, Guignard R, Wissmeyer M, Seeck M, et al. Clinical applications of hybrid PET/MRI in neuroimaging. Clin Nucl Med. 2013;38(1):e13-8. doi: 10.1097/RLU.0b013e3182638ea6. [PubMed: 23242058].
  • 3. Lee SJ, Seo HJ, Cheon GJ, Kim JH, Kim EE, Kang KW, et al. Usefulness of integrated PET/MRI in head and neck cancer: a preliminary study. Nucl Med Mol Imaging. 2014;48(2):98-105. doi: 10.1007/s13139-013-0252-2. [PubMed: 24900149]. [PubMed Central: PMC4028474].
  • 4. Khiewvan B, Torigian DA, Emamzadehfard S, Paydary K, Salavati A, Houshmand S, et al. Update of the role of PET/CT and PET/MRI in the management of patients with cervical cancer. Hell J Nucl Med. 2016;19(3):254-68. doi: 10.1967/s002449910409. [PubMed: 27824966].
  • 5. Aras M, Ones T, Dane F, Nosheri O, Inanir S, Erdil TY, et al. False positive FDG PET/CT resulting from fibrous dysplasia of the bone in the work-up of a patient with bladder cancer: case report and review of the literature. Iran J Radiol. 2012;10(1):41-4. doi: 10.5812/iranjradiol.10303. [PubMed: 23599713]. [PubMed Central: PMC3618905].
  • 6. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27(4):331-71. doi: 10.1016/j.preteyeres.2008.05.001. [PubMed: 18653375]. [PubMed Central: PMC3682685].
  • 7. Ajlan RS, Silva PS, Sun JK. Vascular endothelial growth factor and diabetic retinal disease. Semin Ophthalmol. 2016;31(1-2):40-8. doi: 10.3109/08820538.2015.1114833. [PubMed: 26959128].
  • 8. Marneros AG. Increased VEGF-A promotes multiple distinct aging diseases of the eye through shared pathomechanisms. EMBO Mol Med. 2016;8(3):208-31. doi: 10.15252/emmm.201505613. [PubMed: 26912740]. [PubMed Central: PMC4772957].
  • 9. Kovach JL, Schwartz SG, Flynn HW Jr, Scott IU. Anti-VEGF treatment strategies for wet AMD. J Ophthalmol. 2012;2012:786870. doi: 10.1155/2012/786870. [PubMed: 22523653]. [PubMed Central: PMC3317200].
  • 10. Mirabelli P, Peebo BB, Xeroudaki M, Koulikovska M, Lagali N. Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model. Exp Eye Res. 2014;125:118-27. doi: 10.1016/j.exer.2014.06.006. [PubMed: 24933712].
  • 11. Gaykema SB, Brouwers AH, Lub-de Hooge MN, Pleijhuis RG, Timmer-Bosscha H, Pot L, et al. 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med. 2013;54(7):1014-8. doi: 10.2967/jnumed.112.117218. [PubMed: 23651946].
  • 12. Gaykema SB, Schroder CP, Vitfell-Rasmussen J, Chua S, Oude Munnink TH, Brouwers AH, et al. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Clin Cancer Res. 2014;20(15):3945-54. doi: 10.1158/1078-0432.CCR-14-0491. [PubMed: 25085789].
  • 13. Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, et al. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J Nucl Med. 2015;56(1):63-9. doi: 10.2967/jnumed.114.144840. [PubMed: 25476536].
  • 14. van Asselt SJ, Oosting SF, Brouwers AH, Bongaerts AH, de Jong JR, Lub-de Hooge MN, et al. Everolimus reduces (89)Zr-bevacizumab tumor uptake in patients with neuroendocrine tumors. J Nucl Med. 2014;55(7):1087-92. doi: 10.2967/jnumed.113.129056. [PubMed: 24790218].
  • 15. van der Bilt AR, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Schroder CP, Pot L, Kosterink JG, et al. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clin Cancer Res. 2012;18(22):6306-14. doi: 10.1158/1078-0432.CCR-12-0406. [PubMed: 23014526].
  • 16. Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H, et al. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med. 2010;51(5):761-7. doi: 10.2967/jnumed.109.071043. [PubMed: 20395337].
  • 17. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-7. doi: 10.1056/NEJM199412013312203. [PubMed: 7526212].
  • 18. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274(33):23463-7. doi: 10.1074/jbc.274.33.23463. [PubMed: 10438525].
  • 19. Gamulescu MA, Radeck V, Lustinger B, Fink B, Helbig H. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration. Int Ophthalmol. 2010;30(3):261-6. doi: 10.1007/s10792-009-9318-7. [PubMed: 19633973].
  • 20. Schmucker C, Antes G, Lelgemann M. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2010;248(3):451-2. author reply 453-4. doi: 10.1007/s00417-009-1249-5. [PubMed: 20012081].
  • 21. Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: A 5-year retrospective analysis. Ophthalmology. 2015;122(5):1008-15. doi: 10.1016/j.ophtha.2014.12.017. [PubMed: 25687024]. [PubMed Central: PMC4414677].
  • 22. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK; Diabetic Retinopathy Clinical Research Network, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860-7. doi: 10.1016/j.ophtha.2007.05.062. [PubMed: 17698196]. [PubMed Central: PMC2245885].
  • 23. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2. Ophthalmology. 2010;117(6):1078-1086 e2. doi: 10.1016/j.ophtha.2010.03.045. [PubMed: 20416952].
  • 24. Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: The BEVORDEX study. Ophthalmology. 2014;121(12):2473-81. doi: 10.1016/j.ophtha.2014.07.002. [PubMed: 25155371].
  • 25. Dorta P, Kychenthal A. Spectral-domain optical coherence tomography of the macula in preterm infants treated with bevacizumab for retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina. 2015;46(3):321-6. doi: 10.3928/23258160-20150323-04. [PubMed: 25856817].
  • 26. Chen SN, Lian I, Hwang YC, Chen YH, Chang YC, Lee KH, et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: Comparison between ranibizumab and bevacizumab. Retina. 2015;35(4):667-74. doi: 10.1097/IAE.0000000000000380. [PubMed: 25462435].
  • 27. Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2015;56(2):956-61. doi: 10.1167/iovs.14-15842. [PubMed: 25613938].
  • 28. Ye Z, Ji YL, Ma X, Wen JG, Wei W, Huang SM. Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits. Int J Ophthalmol. 2015;8(4):653-8. doi: 10.3980/j.issn.2222-3959.2015.04.02. [PubMed: 26309857]. [PubMed Central: PMC4539635].
  • 29. Jang BS. MicroSPECT and MicroPET imaging of small animals for drug development. Toxicol Res. 2013;29(1):1-6. doi: 10.5487/TR.2013.29.1.001. [PubMed: 24278622]. [PubMed Central: PMC3834443].
  • 30. Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48(8):1313-9. doi: 10.2967/jnumed.107.041301. [PubMed: 17631557].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments